MSLN and graft versus host disease: Owing to their inherent cytotoxicity, lower risk of GvHD, and reduced incidence of CRS, NK cells are ideal for the development of “off-the-shelf” allogeneic cell therapies.7,21 In this study, we demonstrate the potential of anti-MSLN CAR-like NK cell therapy for treating MSLN-positive solid tumors both in vitro and in vivo, supporting the translation of this approach to clinical applications.